Strategic IP Acquisition / Licensing Opportunity: High-Yield Computational Cytogenomics Algorithm

a proprietary, platform-agnostic weighted computational mathematical algorithm that is currently available for outright asset sale, licensing, or strategic acquisition with a trailing royalty structure. This mathematical engine functions as an advanced clinical decision-support plug-in designed to integrate seamlessly into existing digital software, NGS data pipelines, or array-CGH analysis workflows. It explicitly targets and resolves the high labor overhead associated with manual cytogenetic interpretation by automating the resolution of complex sex chromosome aneuploidies (SCAs) and multi-line mosaicism. Solving a Massive Clinical Bottleneck: Klinefelter syndrome and its variants are vastly undiagnosed or misdiagnosed in modern healthcare. Because standard diagnostic tools frequently fail to flag these non-linear chromosomal profiles early, individuals are routinely directed to the wrong clinical departments—undergoing inappropriate or ineffective treatments in psychiatry, oncology, or behavioral clinics for ADHD. This algorithm provides the precise mathematical computational framework required to catch these hidden variants early and accurately at the genomic level. Proven Performance Metric: In a recent clinical stress-test of a highly complex, the algorithm achieved a 100% diagnostic accuracy score. It successfully mapped, isolated, and differentiated a concurrent presentation of a mosaic father, a son with Klinefelter syndrome (47,XXY via Meiosis I non-disjunction), and a second son with Jacobs syndrome (47,XYY via Meiosis II non-disjunction)—a scenario that typically triggers extensive, manual human validation. Value Proposition for Your Ecosystem: Market Expansion: Opens up new diagnostic pipelines by capturing the vast, currently undetected population of clinical variants. Drastic Throughput Increase: Minimizes costly lab review hours for clinical geneticists by instantly automating complex edge cases. Agnostic Architecture: Formulated as a pure, lightweight mathematical engine that easily wraps into standard clinical software environments. A non-confidential executive summary is available for your review. To protect the proprietary intellectual property, underlying code architecture and weight matrices will be disclosed to your technical team exclusively upon execution of a standard Mutual Non-Disclosure Agreement (MNDA). Are you the correct contact to discuss potential portfolio alignment, or is there a specific member of your corporate development/technology acquisition team I should connect with? Sincerely, Franco Gentile CEO GENTILEX RESEARCH MONTREAL CANADA MOBILE 1 514 236 9875